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Results Fifteen patients were treated. No DLT occurred 
with 15.5, 25, or 35 mg/m2 ombrabulin. In the 50 mg/m2 
group, one patient had Grade 3 lymphopenia, and another 
experienced Grade 2 hypertension and Grade 3 diarrhea 
judged as DLTs. The most frequent related adverse events 
in this group were diarrhea, nausea, and hypertension. Two 
patients had Grade 3 anemia, one at the 15.5 mg/m2 and the 
other at the 50 mg/m2. No AEs necessitating dose reduction 
or Grade 4 AEs were observed. Overall, five patients had 
stable disease. Pharmacokinetic parameters were compara-
ble to those in non-Japanese patients.
Conclusions Ombrabulin treatment once every 3 weeks 
was well tolerated in Japanese patients with advanced 
solid tumors. The dose recommended is 50 mg/m2, as in 
Caucasian patients. The safety and pharmacokinetic pro-
files were comparable between Japanese and Caucasian 
patients (funded by Sanofi; ClinicalTrials.gov number, 
NCT00968916).
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Introduction
The concept that tumor growth and survival are critically 
dependent on the development of new blood vessels has 
led to the development of therapeutics that target angiogen-
esis [1]. There are currently two principal mechanisms by 
which vascular-targeted agents exert their effects: inhibi-
tion of angiogenesis (antiangiogenic agents) and destruc-
tion of the existing tumor vasculature (vascular disrupting 
agents, VDAs) [2]. By virtue of their high proliferation 
rate, endothelial cells of tumor blood vessels are far more 
sensitive to VDAs than are cells of normal blood vessels 
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[3]. On the molecular level, ombrabulin, one such VDA, 
binds to the colchicine site of tubulin and inhibits polym-
erization, causing destabilization of the cytoskeleton, shape 
change, and vascular collapse [4, 5]; the resultant reduction 
in blood flow leads to tumor necrosis. VDAs have demon-
strated varying degrees of success in the clinical setting. 
Colchicine was the first tubulin-binding agent discovered 
to have antivascular effects, which resulted in hemorrhagic 
necrosis in human tumors [6]. However, its toxicity pre-
vented further clinical evaluation. Tubulin-binding agents 
such as vincristine and vinblastine are potent anticancer 
drugs currently used. These agents induce extensive vascu-
lar damage in animal tumors at doses close to their respec-
tive maximum tolerated doses (MTDs) [7, 8]. Despite these 
advances, more potent VDAs are currently being sought.
Combretastatins are a class of compounds isolated from 
the South African tree Combretum caffrum that have a 
high affinity for tubulin at or near the colchicine-binding 
site. Combretastatin A4 (CA-4) [9], in particular, is highly 
cytotoxic [10, 11]. Combretastatin A4 phosphate (CA4P), 
a prodrug of CA-4, and ombrabulin (AVE8062), a syn-
thetic analog of CA4P (Fig. 1), have been shown to sup-
press tumor growth by reducing tumor blood flow in dif-
ferent cancers in vivo [12–15]. In mice, ombrabulin began 
to restrict tumor perfusion within 15 min after the start of 
infusion; peak effect occurred after 6 h, with permanent 
widespread tumor necrosis after 24 h [16]. As with other 
VDAs, perfusion changes seen in normal tissues were 
largely reversible [17], indicating that tumor tissue is more 
susceptible to ombrabulin-induced reduction in blood 
flow [18]. Results from toxicological studies suggest that 
ombrabulin mainly affects cells with high turnover, includ-
ing bone marrow, circulating blood cells, and intestinal 
epithelia [3]. However, cardiovascular effects, including 
myocardial degeneration and necrosis, hypertension, and 
premature ventricular contractions, were also noted with 
high-dose ombrabulin in different species [3].
The recommended dose derived from a phase I dose-
escalation study conducted in Europe, in which ombrabu-
lin was administered once every 3 weeks over a dose 
range of 6–60 mg/m2, was 50 mg/m2 [19]. On the basis of 
these results, we conducted a new phase I study designed 
to evaluate DLTs and MTD for Japanese patients with 
advanced solid tumors and to assess pharmacokinetics and 
safety profiles between Japanese and Caucasian patients.
Patients and methods
Study conduct
The study was approved by the institutional review boards/
ethics committees and was conducted in accordance with 
the Declaration of Helsinki. All patients gave written 
informed consent prior to enrollment.
Patient selection
Adult Japanese patients with advanced histologically or 
cytologically proven solid malignant tumors refractory 
to conventional treatment or without standard therapeutic 
options were eligible. The main inclusion criteria were the 
following: (1) age ranging from 20 to 75 years, (2) Eastern 
Cooperative Oncology Group (ECOG) performance sta-
tus of <2, and (3) life expectancy of more than 12 weeks. 
The main exclusion criteria were as follows: (1) concur-
rent treatment with any other anticancer therapy, includ-
ing chemotherapy, immunotherapy, radiotherapy, targeted 
therapy, or gene therapy, (2) washout period of <28 days 
from prior anticancer therapies (chemotherapy, targeted 
agents, immunotherapy, and radiotherapy) or any investi-
gational treatment, (3) symptomatic brain metastases and 
carcinomatous leptomeningitis, (4) inadequate organ func-
tion including neutrophil count of <1.5 × 109/L, platelet 
count of <100 × 109/L, hemoglobin level of <9.0 g/dL, 
creatinine clearance of <60 mL/min, total bilirubin level 
of ≥1.5 mg/dL, alanine aminotransferase (ALT) or aspar-
tate aminotransferase (AST) level of >1.5 times the upper 
limits of normal (ULN) of the institutional norms, and 
alkaline phosphatase (AP) level of >2.5 times ULN of the 
institutional norms, (5) a left ventricular ejection fraction 
(LVEF) of <50 % by echocardiography, (6) a baseline QTc 
interval of >0.45, (7) hypertension defined as systolic blood 
pressure (SBP) of >140 mmHg or diastolic BP (DBP) of 
>90 mmHg, and (8) 1 or more episodes of ventricular tach-
ycardia with 3 or more consecutive premature beats with a 
frequency of ≥180 beats/min.
Study design
This was a multi-center, open-label phase I study designed 
to test the safety and pharmacokinetics (PK) of ombrabu-
lin (Sanofi Oncology, Vitry-sur-Seine, France) in Japanese 
patients with advanced malignant solid tumors (Clinical-
Trials.gov: NCT00968916). The primary objective was 
Fig. 1  Chemical structure of ombrabulin (AVE8062)
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to determine the maximum tolerated dose (MTD) on the 
basis of the incidence of dose-limiting toxicity (DLT) dur-
ing Cycle 1. Ombrabulin was administered as a 30-min IV 
infusion once every 3 weeks to sequential cohorts of three 
patients at a dose 15.5, 25, 35, or 50 mg/m2; the study 
design allowed for the addition of three patients if one 
patient experienced a DLT at that dose. The decision to 
proceed to the next dose was primarily based on the iden-
tification of DLTs. The dose escalation was discontinued 
when two or more of six patients experienced a DLT; the 
dose at which this occurred was designated the maximum 
administered dose (MAD), and additional patients were 
to be enrolled in the previous dose level (the MTD) until 
at least six patients could be evaluated. The starting dose 
and dose-escalation increments were based on results from 
previous trials [19–21] to allow for a direct comparison of 
results with Japanese versus Caucasian patients. Because 
this is the first phase I trial in Japanese patients, the start-
ing dose of 15.5 mg/m2 was selected since no DLTs had 
been reported at this dose level in monotherapy and com-
bination studies, and imaging studies showed evidence of 
tumor blood flow shutdown [20]. The MTD for ombrabu-
lin monotherapy with a triweekly schedule was previously 
established at 50 mg/m2 [19]; thus, 50 mg/m2 was the high-
est dose used in the present study. Although the results sug-
gest that this is not the MTD for Japanese patients, the dose 
range was not extended to identify the MTD, and the study 
was completed.
Safety evaluations
The safety population was to be the all enrolled patients 
who received at least 1 (even if incomplete) infusion of 
ombrabulin. AEs were graded according to the National 
Cancer Institute Common Terminology Criteria (NCI-
CTC) version 3.0. Hematology/biochemistry and urinalysis 
was evaluated weekly. Cardiovascular evaluations included 
a clinical examination, 12-lead and 24-h Holter ECGs, 
and plasma levels of creatine phosphokinase (CPK), CK-
MB, and troponin I. Echocardiography, chest X-ray, and 
brain MRI were performed every other cycle from the 
second cycle. To qualify as a DLT, clinical AEs or labora-
tory abnormalities had to be drug-related as assessed by 
the investigator during cycle 1. Non-vascular hematologic 
DLTs were defined as follows: Grade 4 febrile neutropenia, 
Grade 4 neutropenia lasting >5 days, Grade 4 thrombocy-
topenia (platelet counts of <25 × 109/L), or hemoglobin 
level of <6.5 g/dL. Non-vascular non-hematologic DLTs 
were defined as any Grade 3–4 events except nausea; vom-
iting well controlled under antiemetic treatment; increases 
in AST, ALT, or AP levels lasting <8 days; or hypersensi-
tivity well controlled under antihistamine and corticoster-
oid treatment. Non-vascular renal DLTs were defined as 
calculated creatinine clearance of <40 mL/min. Cardiovas-
cular DLTs were defined as follows: documented angina 
pectoris or arterial thromboembolism; hypertension with 
systolic BP of ≥180 mmHg or diastolic BP of ≥120 mmHg 
for at least 2 successive measurements, or acute impair-
ment of target organ (the brain, heart, and kidney); hypo-
tension grade of ≥2 or systolic BP of <90 mmHg for at 
least 2 successive measurements; positive cardiac mark-
ers with troponin-I value greater than the pathological 
limit defined by the manufacturer as a sign of myocardial 
necrosis, cardiac ischemia/infarction with ST- and T-wave 
changes suggesting ischemia; decreased cardiac left ven-
tricular function with resting ejection fraction below 50 % 
with ≥20 % decline of resting ejection fraction from base-
line value; ventricular arrhythmia accompanied by at least 
1 series of ventricular tachycardia with 3 or more consecu-
tive premature beats, with a frequency of ≥180 beats/min; 
or any other Grade 3–4 vascular events, except for some 
adverse events at tumor site, such as intratumor hemor-
rhage or tumor hemorrhagic necrosis, that are not life-
threatening. A patient was to be considered as evaluable for 
a DLT if the patient had received at least one administration 
of ombrabulin and if a complete safety evaluation had been 
performed during Cycle 1.
Tumor response evaluation
The efficacy endpoint in evaluable patients was the objec-
tive tumor response as defined by the rules set forth in the 
Response Evaluation Criteria in Solid Tumors (RECIST 
1.0) [22]. Patients with an objective response were defined 
by pooling those who exhibited a complete response (CR) 
or a partial response (PR). Tumor assessments of all target 
or non-target lesions and brain magnetic resonance imaging 
(MRI)/computed tomography (CT) were performed within 
28 days of first dose administration. Subsequent assess-
ments were performed every 2 cycles until unacceptable 
disease progression or treatment discontinuation.
Pharmacokinetics
Plasma samples were obtained from all patients before 
infusion, immediately prior to the end of the 30-min infu-
sion (EOI), and at 5, 10, 25, 45, and 60 min, and 2, 4, 6, 
10, 24, and 48 h after EOI at Cycle 1. During Cycles 2–4, 
samples were collected immediately prior to the EOI and 
10 min after infusion. Concentrations of ombrabulin and 
its active metabolite RPR258063 were measured by LC–
MS/MS. The limit of quantification (LOQ) was 2.00 ng/
mL for both analytes. All PK parameters, including maxi-
mum plasma concentration (Cmax), area under the curve 
(AUC), terminal half-life (T1/2z), clearance (CL), and vol-
ume of distribution at steady state (VDss), were calculated 
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by non-compartmental analysis using WinNonlin software 
(version 5.2.1). Pharmacokinetic parameters were analyzed 
using descriptive statistics, including mean and standard 
deviation. Statistical modeling was used to assess dose pro-
portionality of Cmax and AUC.
Results
Patient characteristics and treatment
Overall, 15 Japanese patients were recruited and treated in 
two investigational centers in Japan from September 2009 
to August 2011. There were no important deviations to the 
protocol. Three patients each were exposed to ombrabu-
lin at a dose of 15.5, 25, or 35 mg/m2; six patients were 
exposed to 50 mg/m2 ombrabulin. One patient (6.7 %) dis-
continued study treatment due to diarrhea and hyperten-
sion. During the study, disease progression was observed 
in 14 patients (93.3 %), and no deaths were reported. Base-
line characteristics of nine female (60.0 %) and six male 
patients (40.0 %) are summarized in Table 1. The treated 
patients had a performance status (PS) of 0 (46.7 %) or 1 
(53.3 %) at baseline. The median (range) age was 62 (29–
71) years, with most patients in the 50–64 years of age 
bracket (46.7 %). Almost all patients had metastatic tumors 
at baseline. The most frequent primary tumor sites were 
lung (6 of 15 patients), muscle/soft tissue (2 of 15 patients), 
and breast (2 of 15 patients). The median number of cycles 
was 2.0 (range 1–7) for doses ≤35 mg/m2 and 2.5 for the 
50 mg/m2 dose.
Dose-limiting toxicity
The primary safety variable was the incidence of DLTs at 
Cycle 1. No DLTs occurred at 15.5, 25, or 35 mg/m2. One 
patient of six from the 50 mg/m2 treatment group experi-
enced two incidences of DLT: Grade 2 hypertension, which 
occurred at the end of infusion and resolved that day, and 
Grade 3 diarrhea, which occurred during the subsequent 
2 days and resolved the next day. The MTD defined in the 
protocol was not identified. However, since a dose higher 
than the global recommended dose (50 mg/m2) could not 
be tested, further dose escalation was not investigated. The 
Table 1  Patient baseline characteristics
a
 Malignant mesothelioma and adenocarcinoma of unknown primary
N patients treated Dose level (mg/m2) Total
15.5 25 35 50
3 3 3 6 15
Male, N (%) 1 (33.3 %) 1 (33.3 %) 1 (33.3 %) 3 (50.0 %) 6 (40.0 %)
Age in years, median (range) 60.0 (57–63) 67.0 (62–71) 61.0 (45–62) 63.0 (29–69) 62.0 (29–71)
Number of previous regimens, median (range) 5.0 (3–5) 5.0 (3–11) 0.0 (0–9) 2.5 (0–9) 3.0 (0–11)
Prior radiotherapy 2 (66.7 %) 2 (66.7 %) 2 (66.7 %) 1 (16.7 %) 7 (46.7 %)
Prior surgery 1 (33.3 %) 2 (66.7 %) 3 (100 %) 4 (66.7 %) 10 (66.7 %)
Prior chemotherapy 3 (100 %) 3 (100 %) 2 (66.7 %) 5 (83.3 %) 13 (86.7 %)
Prior hormonotherapy 0 1 (33.3 %) 1 (33.3 %) 0 2 (13.3 %)
Other prior therapies 0 0 0 1 (16.7 %) 1 (6.7 %)
ECOG performance status, N (%)
 0 0 1 (33.3 %) 2 (66.7 %) 4 (66.7 %) 7 (46.7 %)
 1 3 (100 %) 2 (66.7 %) 1 (33.3 %) 2 (33.3 %) 8 (53.3 %)
Primary tumor, N (%)
 Lungs 3 (100 %) 1 (33.3 %) 1 (33.3 %) 1 (16.7 %) 6 (40.0 %)
 Muscle/soft tissue 0 0 0 2 (33.3 %) 2 (13.3 %)
 Breast 0 1 (33.3 %) 1 (33.3 %) 0 2 (13.3 %)
 Head/neck 0 1 (33.3 %) 0 0 1 (6.7 %)
 Esophagus 0 0 0 1(16.7 %) 1 (6.7 %)
 Othera 0 0 1 (33.3 %) 1 (16.7 %) 2 (13.3 %)
 Thyroid 0 0 0 1 (16.7 %) 1 (6.7 %)
Extent of disease at study entry, N (%)
 Metastatic 3 (100 %) 3 (100 %) 3 (100 %) 5 (83.3 %) 14 (93.3 %)
 Locally advanced 0 0 0 1 (16.7 %) 1 (6.7 %)
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dose level of 50 mg/m2 ombrabulin was therefore consid-
ered as the MAD and recommended dose (RD)/MTD in 
Japanese patients with advanced solid tumors.
Overall safety
All patients experienced non-serious AEs; 14 of 15 patients 
experienced AEs considered related to study treatment. 
The most common AEs are summarized in Table 2. Over-
all, there were no AEs leading to death, no serious adverse 
events (SAEs) or those leading to dose reduction, no Grade 
4 AEs, and no Grade 4 clinical laboratory abnormalities. In 
addition, no severe myelotoxicity or abnormal increase in 
cardiac markers was observed. Grade 1–2 neutropenia was 
observed in 8 of 15 patients (53 %) across all dose groups. 
Anemia was present in 10 of 15 (67 %) patients at base-
line; after receiving ombrabulin, most patients (12 of 15) 
had anemia, including one patient each at 15.5 and 50 mg/
m2 at Grade 3. There were no Grade 3–4 abnormalities in 
liver or renal functions. The most common AEs at 50 mg/
m2 (RD) were diarrhea (five of six patients), nausea (five of 
six patients), and hypertension (four of six patients); 50 % 
of patients experienced decreased appetite, headache, con-
junctival hyperemia, sinus bradycardia, hot flush, vomiting, 
or fatigue. One patient exposed to 50 mg/m2 had treatment-
related Grade 2 and Grade 3 LV dysfunction (LVEF: 37 %) 
at Cycles 5 and 7, respectively.
Pharmacokinetics
PK analyses at Cycle 1 were performed on the PK-eval-
uable population by using actual sampling times, dos-
ing times, and times of administration for each patient. 
Plots of the mean ombrabulin and RPR258063 plasma 
concentrations versus time profiles in patients for each 
ombrabulin dose level are shown in Fig. 2. Ombrabulin and 
RPR258063 PK parameters obtained at Cycle 1 are sum-
marized in Table 3. After a single IV administration, maxi-
mum ombrabulin concentrations were observed at the end 
of infusion; concentrations rapidly declined and were quan-
tifiable up to 1.5 or 2.5 h after administration. Ombrabulin 
was rapidly converted to RPR258063, the active metabo-
lite, which appeared rapidly after end of infusion; exposure 
to the metabolite was found to be about 1.8-fold higher 
Table 2  The most common adverse events observed in at least two patients at 50 mg/m2
AE is defined as an adverse event that is reported during the on-treatment period (from the first dose to 30 days after the last dose)
PT preferred term (MedDRA 14.0 and graded using NCI CTC version 3.0)
Dose level (mg/m2), N (%)
15.5 (N = 3) 25 (N = 3) 35 (N = 3) 50 (N = 6)
All grades Grades 3 and 4 All grades Grades 3 and 4 All grades Grades 3 and 4 All grades Grades 3 and 4
Patients with any AE 3 (100 %) 0 3 (100 %) 0 3 (100 %) 0 6 (100 %) 3 (50.0 %)
Patients with any related AE 3 (100 %) 0 2 (66.7 %) 0 3 (100 %) 0 6 (100 %) 2 (33.3 %)
Patients with any serious AE 0 0 0 0 0 0 0 0
AE (PT: alphabetical order)
 Blood bilirubin increased 0 0 0 0 0 0 2 (33.3 %) 0
 Chills 0 0 0 0 0 0 2 (33.3 %) 0
 Conjunctival hyperemia 0 0 0 0 0 0 3 (50.0 %) 0
 Constipation 1 (33.3 %) 0 1 (33.3 %) 0 0 0 1 (16.7 %) 0
 Decreased appetite 2 (66.7 %) 0 1 (33.3 %) 0 1 (33.3 %) 0 3 (50.0 %) 0
 Diarrhea 1 (33.3 %) 0 0 0 1 (33.3 %) 0 5 (83.3 %) 1 (16.7 %)
 Fatigue 1 (33.3 %) 0 1 (33.3 %) 0 1 (33.3 %) 0 3 (50.0 %) 0
 Headache 0 0 0 0 1 (33.3 %) 0 3 (50.0 %) 0
 Hot flush 0 0 0 0 1 (33.3 %) 0 3 (50.0 %) 0
 Hypertension 1 (33.3 %) 0 0 0 1 (33.3 %) 0 4 (66.7 %) 0
 Injection site phlebitis 0 0 0 0 1 (33.3 %) 0 2 (33.3 %) 0
 Nasopharyngitis 1 (33.3 %) 0 2 (66.7 %) 0 0 0 1 (16.7 %) 0
 Nausea 2 (66.7 %) 0 0 0 2 (66.7 %) 0 5 (83.3 %) 0
 Pyrexia 1 (33.3 %) 0 0 0 0 0 2 (33.3 %) 0
 Sinus bradycardia 0 0 0 0 0 0 3 (50.0 %) 0
 Ventricular extrasystoles 0 0 0 0 2 (66.7 %) 0 1 (16.7 %) 0
 Vomiting 2 (66.7 %) 0 0 0 1 (33.3 %) 0 3 (50.0 %) 0
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than to ombrabulin. T1/2z (around 11 h) for RPR258063 
was considerably longer in comparison with ombrabu-
lin. Ombrabulin exhibited a high plasma CL (95.2 L/h) 
and a low VDss (30.9 L), corresponding to a short T1/2z 
(15.7 min). Ombrabulin Cmax, AUC, and AUClast did not 
deviate significantly from dose proportionality over the 
15.5–50 mg/m2 dose range. RPR258063 exposure param-
eters were also dose proportional within this dose range. 
No dose effect was observed with T1/2z or CL. No notable 
changes were observed in plasma concentration of ombrab-
ulin and RPR258063 for cycles 1–4.
Antitumor activity
Tumor response (best overall response), assessed accord-
ing to RECIST 1.0 criteria, revealed that 5 of 15 patients 
(33.3 %), including two patients with lung cancer, two 
patients with muscle/soft tissue cancer, and one patient with 
cancer of unknown primary origin, had stable disease (SD) at 
the end of the trial as assessed by the investigator. Sustained 
SDs longer than 4 months (maximum 7.2 months) were con-
firmed in two of five patients. Four of six patients (66.7 %) 
from the 50 mg/m2 dose group had SD, while among the nine 
patients in the lower dose groups (15.5, 25, and 35 mg/m2), 
one patient receiving a dose of 15.5 mg/m2 had SD (Table 4).
Discussion
Following the protocol used in an earlier phase I trial con-
ducted in USA and Europe [19], we conducted a study in 
which Japanese patients were given ombrabulin once every 
3 weeks at a dose of 15.5, 25, 35, or 50 mg/m2. No DLTs 
were observed up to 35 mg/m2. Only one of six patients 
treated at 50 mg/m2 experienced DLTs, including tran-
sient Grade 2 hypertension and Grade 3 diarrhea. Thus, 
the RD for Japanese patients was determined to be 50 mg/
m2. Although we had not yet reached the MTD for Japa-
nese patients at 50 mg/m2, the study was not extended to 
include higher doses since Sessa et al. [23] had determined 
the RD for phase II studies to be 50 mg/m2. In their study, 
one patient experienced DLT (Grade 3 abdominal pain) at a 
dose of 50 mg/m2, and another experienced Grade 3 tumor 
pain/Grade 3 hypertension at 60 mg/m2. Although adverse 
events were generally more common, the safety profile 
observed in our study is very similar to that in a study con-
ducted in USA and Europe [19]. In that study, the most 
common drug-related adverse events at the RD of 50 mg/
m2 were headache (31 %), asthenia (28 %), abdominal pain 
(26 %), nausea (26 %), diarrhea (23 %), and hypertension 
(23 %); these too were mainly mild to moderate [19].
Results compiled from early-phase clinical trials involv-
ing VDAs have demonstrated a profound occurrence of 
cardiovascular events, including hypertension, tachycar-
dia, bradycardia, atrial fibrillation, and myocardial infarc-
tion [24]. In the present study, three patients with a medi-
cal history of hypertension (one patient from the 35 mg/m2 
and two patients from the 50 mg/m2 groups) experienced 
SBP ≥20 mmHg increase from baseline and ≥180 mmHg 
within an hour of ombrabulin treatment; blood pressure 
returned to baseline levels on the same or next day without 
any corrective treatment. Similarly, in a phase I trial with 
ombrabulin, Sessa et al. [23] reported a 23 % incidence 
of mild to moderate hypertension that was rapid in onset 
and transient. In the one patient in whom we noted treat-
ment-related LV dysfunction, it was not considered a seri-
ous event, even though it had been present for 5 months, 
because LVEF had been low (54 %) at baseline. Other 
reported cardiotoxicities include Grade 1–2 atypical chest 
pain with evidence of ischemia on ECG and transient QTc 
prolongation [24]. We did note one patient in the 50 mg/m2 
treatment group with a Grade 1 increase in troponin I.
Fig. 2  Mean plasma concentration–time profiles of ombrabulin 
and its major metabolite (RPR258063) in Cycle 1. a Ombrabulin, b 
RPR258063
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No dose effect was observed on terminal elimination 
half-life or clearance of ombrabulin or on terminal elimi-
nation half-life of RPR258063. The PK profiles for both 
ombrabulin and RPR258063 determined in our study were 
comparable to those obtained by Sessa et al. [19] in Cauca-
sian subjects.
This was a phase I study, and tumor response was not 
a primary endpoint. No patient had a complete or partial 
response as the best response, although 5 of 15 patients 
(33.3 %) overall and four of six patients (66.7 %) from 
the highest dose group (50 mg/m2) had SD at the end of 
the trial. In the preceding phase I study in non-Japanese 
patients treated with 50 mg/m2 ombrabulin [19], a sig-
nificant increase in circulating endothelial cells (CECs), 
a potential predictive/prognostic biomarker for antian-
giogenic treatment efficacy [25, 26] and quantitative 
pharmacodynamic biomarker of VDA bioactivity [27], 
was reported in 11 out of 15 tested patients, potentially 
reflecting maximal acute vascular damage, and one patient 
showed partial response. This increase in CECs reported 
by Sessa et al. was probably due to variations in the tim-
ing of tumor response, and an optimal timing for use of this 
parameter should be explored.
In summary, a 30-min infusion of up to 50 mg/m2 
ombrabulin administered to Japanese patients once every 
3 weeks is well tolerated with limited cardiovascular 
adverse events. Therefore, 50 mg/m2 is considered the RD 
for Japanese patients with advanced solid tumors being 
treated with a single agent.
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Table 3  Ombrabulin (a) and RPR258063 (b) pharmacokinetic parameters after single ombrabulin infusion
NA, not applicable; Cmax, maximum plasma concentration observed; AUC, area under the concentration versus time curve extrapolated to infin-
ity; t1/2z, terminal elimination half-life calculated using the following equation: t1/2z = 0.693 × λz; CL, total body clearance calculated using the 
following equation: CL = dose/AUC, for ombrabulin only; VDss, volume of distribution at the steady state after single dose
a
 n = 2, mean (t1/2z not calculable)
b
 n = 2, mean (t1/2z not calculable)
c
 n = 5 (t1/2z not calculable)
d
 n = 14
e
 n = 2, mean
f
 n = 12
g
 AUC(RPR258063)/AUC(ombrabulin)
Ombrabulin dose Plasma ombrabulin (mean ± SD) Total
15.5 mg/m2 25 mg/m2 35 mg/m2 50 mg/m2
N patients treated 3 3 3 6 15
(a) Ombrabulin
 Cmax (ng/mL) 766 ± 75.7 890 ± 322 1,300 ± 309 1,800 ± 334 NA
 AUC (ng h/mL) 305 ± 38.8 443a 602b 750 ± 190 NA
 t1/2z (min) 12.6 ± 0.930 12.8a 17.6b 17.6 ± 4.31 15.7 ± 4.41
 CL (L/h) 68.8 ± 8.59 97.1a 93.0b 108 ± 39.9 95.2 ± 31.3
 VDss (L) 21.0 ± 2.52 33.2a 31.5b 34.9 ± 11.6 30.9 ± 9.59
(b) RPR258063
Cmax (ng/mL) 110 ± 35.5 192 ± 55.0 313 ± 20.2 478 ± 47.0 NA
AUC (ng h/mL) 345 ± 111 881 ± 251 1,020 ± 212 1,430 ± 307c NA
t1/2z (h) 7.49 ± 3.96 13.8 ± 6.70 12.0 ± 1.15 10.4 ± 3.21c 10.8 ± 4.22d
Metabolic ratiog (AUC) 1.18 ± 0.551 1.85e 1.91e 2.14 ± 0.672c 1.81 ± 0.632f
Table 4  Tumor responses Best overall response [n (%)] Dose level (mg/m2) Total (N = 15)
15.5 (N = 3) 25 (N = 3) 35 (N = 3) 50 (N = 6)
Stable disease (SD) 1 (33.3 %) 0 0 4 (66.7 %) 5 (33.3 %)
Progressive disease (PD) 2 (66.7 %) 3 (100 %) 3 (100 %) 1 (16.7 %) 9 (60.0 %)
Not applicable/not assessed 0 0 0 1 (16.7 %) 1 (6.7 %)
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